US 10537560
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
granted A61KA61K31/416A61K31/437
Quick answer
US patent 10537560 (P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD) held by Fulcrum Therapeutics, Inc. expires Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Fulcrum Therapeutics, Inc.
- Grant date
- Tue Jan 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 28
- CPC classes
- A61K, A61K31/416, A61K31/437, A61K31/4418, A61K31/4439